Latest Quinazolines Stories

2009-08-02 12:37:18

Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

2009-07-30 07:00:00

WILMINGTON, Del., July 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the company has submitted a New Drug Application to the U.S.

2009-07-27 15:20:00

The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.

2009-06-29 07:00:00

Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli Lilly and Roche Will Drive Growth, According to a New Report from Decision Resources WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of targeted agents as well as increased use of existing agents in the maintenance setting...

2009-06-02 14:32:12

A U.S.-led international study suggests the combination of two drugs can delay disease progression for patients with advanced non-small cell lung cancer. Dr.

2009-05-31 09:25:00

The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday.

2009-05-28 07:00:00

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc.

2009-05-21 13:26:41

A class of drugs already approved as cancer treatments might also help to beat alcohol addiction.

2009-05-19 07:00:00

SAN DIEGO, May 19 /PRNewswire/ -- Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G.

2009-05-14 17:17:00

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company...

Word of the Day
  • a slit in a tire to drain away surface water and improve traction.
The word 'sipe' comes from Old English and is related to 'seep'.